医学
临床终点
限制
心力衰竭
内科学
临床试验
心脏病学
利尿剂
重症监护医学
终点
血流动力学
随机对照试验
代理终结点
回廊的
初级保健
还原(数学)
工作队
任务(项目管理)
初级预防
不利影响
外科
作者
Bianca Larroux,Flavio Tangianu,Aldo Bonaventura
标识
DOI:10.1080/14656566.2026.2702379
摘要
INTRODUCTION: The VICTOR trial evaluated vericiguat in stable, ambulatory HFrEF patients without recent WHF. Its primary composite endpoint of CV death or HF hospitalization resulted neutral. Yet, a significant reduction in CV mortality was observed. AREAS COVERED: We analyzed the results of the VICTOR trial and put them in the broader context of HFrEF, where anticipating WHF events remains a mandatory task to improve the overall prognosis. We discussed oral diuretic intensification (ODI), that should represent an important aspect to be considered in stable HFrEF patients. EXPERT OPINION: Outpatient WHF events are common in well-treated HFrEF patients and future HF trials should consider to regularly capture ODI. Although secondary endpoint analyses should be interpreted as nominal, the reduction in CV mortality in the VICTOR trial cannot be explained solely through prevention of HF progression or an effect on neurohormonal activation and hemodynamic stress. While current evidence for vericiguat is largely derived from patients with recent WHF, as shown in the VICTORIA trial, the findings of the VICTOR trial might provide a rationale for considering vericiguat earlier in the HFrEF treatment pathway, rather than limiting its use exclusively to patients who fail or progress despite quadruple therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI